de-la-Cruz-Merino, L; Gion, M; Cruz, J; Alonso-Romero, JL; Quiroga, V; Moreno, F; Andres, R; Santisteban, M; Ramos, M; Holgado, E; Cortes, J; López-Miranda, E; Cortes, A; Henao, F; Palazon-Carrión, N; Rodríguez, LM; Ceballos, I; Soto, A; Puertes, A; Casas, M; Benito, S; Chiesa, M; Bezares, S; Caballero, R; Jiménez-Cortegana, C; Sánchez-Margalet, V; Rojo, F
(BMC, 2022-12-03)
BACKGROUND: We evaluated a new chemoimmunotherapy combination based on the anti-PD1 monoclonal antibody pembrolizumab and the pyrimidine antimetabolite gemcitabine in HER2- advanced breast cancer (ABC) patients previously ...